IN8BIO, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
IN8BIO, INC. (INAB) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.75 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- IN8BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.96, a 575.86% increase year-over-year.
- IN8BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.29, a 76.61% decline year-over-year.
- IN8BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.24, a 38.00% decline year-over-year.
- IN8BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.00, a 51.22% decline year-over-year.
- IN8BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $8.28, a 1173.85% increase from fiscal 2024.
- IN8BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $0.65, a 58.60% decline from fiscal 2023.
- IN8BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $1.57, a 44.91% decline from fiscal 2022.
- IN8BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $2.85, a 62.45% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.75 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $1.96 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $8.28 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $8.28 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $8.28 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $0.29 10-Q · filed 2025-05-07 | |||
| 2024-12-31 | $0.65 10-K · filed 2025-03-13 | |||
| 2024-09-30 | $0.89 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $1.24 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $1.24 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $1.57 10-K · filed 2024-03-14 | |||
| 2023-09-30 | $1.59 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $1.59 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $2.00 10-Q · filed 2023-05-12 | |||
| 2022-12-31 | $2.85 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $3.67 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $3.69 10-Q · filed 2022-08-12 | |||
| 2022-03-31 | $4.10 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $7.59 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $8.08 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $5.36 10-Q · filed 2021-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |